Search company, investor...

Founded Year

2000

Stage

IPO | IPO

Total Raised

$34.11M

Date of IPO

11/5/2014

Market Cap

0.02B

Stock Price

2.69

About Nexstim

Nexstim is a medical technology company with a focus on non-invasive brain stimulation technology. The company offers products that provide personalized and effective therapies and diagnostics for challenging brain diseases and disorders, such as major depressive disorder and chronic neuropathic pain. Its primary customers are in the healthcare industry, particularly those dealing with neurosurgery and mental health. It was founded in 2000 and is based in Helsinki, Finland.

Headquarters Location

Elimäenkatu 9 B

Helsinki, FI-00510,

Finland

358 9 2727 1710

Loading...

Loading...

Nexstim Patents

Nexstim has filed 23 patents.

The 3 most popular patent topics include:

  • neuropsychology
  • neuroscience
  • electrotherapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/27/2019

3/8/2022

Neurotechnology, Neurophysiology, Neuropsychology, Electrotherapy, Neuroscience

Grant

Application Date

5/27/2019

Grant Date

3/8/2022

Title

Related Topics

Neurotechnology, Neurophysiology, Neuropsychology, Electrotherapy, Neuroscience

Status

Grant

Latest Nexstim News

Nexstim Plc Changes Certified Advisor to Carnegie Investment Bank AB (publ)

Nov 30, 2023

About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain. Nexstim shares are listed on Nasdaq First North Growth Market Finland. For more information, please visit www.nexstim.com Attachment

Nexstim Frequently Asked Questions (FAQ)

  • When was Nexstim founded?

    Nexstim was founded in 2000.

  • Where is Nexstim's headquarters?

    Nexstim's headquarters is located at Elimäenkatu 9 B, Helsinki.

  • What is Nexstim's latest funding round?

    Nexstim's latest funding round is IPO.

  • How much did Nexstim raise?

    Nexstim raised a total of $34.11M.

  • Who are the investors of Nexstim?

    Investors of Nexstim include HealthCap Venture Capital, Finnish Industry Investment, Sitra Ventures, Lundbeckfond Ventures, Ilmarinen Pension Insurance and 6 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.